GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...

The group will coordinate planning around future use of the site, the breadth of options for support to staff and agreeing next steps for the local investment of a £2m legacy donation by GSK.

A 'lasting legacy' will be left by Glaxo Smith Kline when it closes its Ulverston site in 2025 after 75 years. A Task Force has been convened by local MP Michelle Scrogham to look at the support ...

GSK has acquired exclusive global rights to progress the clinical development and commercialisation of GSK’227. Credit: MAXSHOT.PL/Shutterstock. GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Jemperli (dostarlimab) for the treatment of patients with locally advanced ...

Credit: GSK Jesduvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The product was discontinued for business reasons and not for any safety or effectiveness issues.